Overview
This section of our website provides information that is helpful for optimizing immunotherapy.
One page describes circulating tumor DNA (ctDNA), a biomarker for monitoring treatment response and modifications.
Another page includes information on healthcare disparities, such as barriers to care and ways to provide appropriate education for immune-related adverse event (irAE) management.
Recent additions to this section include content about evidence-based immunotherapy guidelines, navigating the cancer survivorship journey, and immunotherapy biomarkers for predicting treatment response and monitoring treatment outcomes.
In the future, the role of different immunotherapy administration methods, and other topics, will be added.
Our Goal is to Help You Help Your Patients
Whether you’re a community-based practitioner or an oncologist at a research institution, this section is designed to help you ensure the best outcomes for your patients.
Count on AIM with Immunotherapy to reflect the latest advancements in treatment and provide you with the most current information and resources.
We hope this section serves as a valuable resource to aid your clinical practice and ultimately improve the lives of the patients for whom you care.